Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $451.94 | 7 | 96.7% |
| Education | $15.27 | 1 | 3.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $184.44 | 3 | $0 (2023) |
| Allergan Inc. | $141.34 | 1 | $0 (2017) |
| Fresenius Kabi USA, LLC | $80.62 | 1 | $0 (2017) |
| ABBVIE INC. | $45.54 | 2 | $0 (2022) |
| PFIZER INC. | $15.27 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $69.44 | 2 | Novartis Pharmaceuticals Corporation ($54.17) |
| 2022 | $45.54 | 2 | ABBVIE INC. ($45.54) |
| 2017 | $352.23 | 4 | Allergan Inc. ($141.34) |
All Payment Transactions
8 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 04/05/2023 | PFIZER INC. | CIBINQO (Drug) | Education | In-kind items and services | $15.27 | General |
| Category: Inflammation & Immunology | ||||||
| 03/09/2023 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $54.17 | General |
| 01/25/2022 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $19.10 | General |
| Category: IMMUNOLOGY | ||||||
| 01/06/2022 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $26.44 | General |
| Category: IMMUNOLOGY | ||||||
| 04/24/2017 | NOVARTIS PHARMACEUTICALS CORPORATION | COSENTYX (Biological) | Food and Beverage | In-kind items and services | $124.19 | General |
| Category: DERMATOLOGY | ||||||
| 04/24/2017 | NOVARTIS PHARMACEUTICALS CORPORATION | COSENTYX (Biological) | Food and Beverage | In-kind items and services | $6.08 | General |
| Category: DERMATOLOGY | ||||||
| 04/06/2017 | Fresenius Kabi USA, LLC | Morphine Sulfate (Drug), Simplist Dilaudid | Food and Beverage | In-kind items and services | $80.62 | General |
| Category: Analgesic/Anesthetic | ||||||
| 03/04/2017 | Allergan Inc. | — | Food and Beverage | In-kind items and services | $141.34 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 255 | 437 | $139,308 | $14,353 |
| 2022 | 6 | 223 | 495 | $122,527 | $12,993 |
| 2021 | 11 | 419 | 695 | $259,354 | $27,729 |
| 2020 | 9 | 326 | 539 | $175,255 | $16,138 |
All Medicare Procedures & Services
34 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 82 | 102 | $40,086 | $5,238 | 13.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 30 | 40 | $23,080 | $3,302 | 14.3% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 44 | 58 | $27,028 | $2,531 | 9.4% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 17 | 21 | $14,679 | $1,184 | 8.1% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 29 | 37 | $8,917 | $1,076 | 12.1% |
| 11104 | Punch biopsy, first skin growth | Office | 2023 | 12 | 13 | $10,871 | $486.22 | 4.5% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 11 | 12 | $8,025 | $292.45 | 3.6% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 30 | 154 | $6,622 | $243.30 | 3.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 78 | 100 | $39,300 | $4,957 | 12.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 37 | 54 | $31,158 | $3,950 | 12.7% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 43 | 58 | $27,028 | $2,426 | 9.0% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2022 | 14 | 16 | $11,184 | $897.46 | 8.0% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2022 | 40 | 255 | $10,965 | $412.25 | 3.8% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 11 | 12 | $2,892 | $350.88 | 12.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 84 | 116 | $66,932 | $9,563 | 14.3% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 88 | 107 | $42,051 | $5,457 | 13.0% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 29 | 29 | $25,143 | $3,448 | 13.7% |
| 17000 | Destruction of skin growth | Office | 2021 | 53 | 71 | $31,117 | $3,040 | 9.8% |
| 17004 | Destruction of 15 or more premalignant skin growths | Office | 2021 | 14 | 18 | $16,056 | $1,481 | 9.2% |
| 17110 | Destruction of up to 14 skin growths | Office | 2021 | 23 | 26 | $17,378 | $1,387 | 8.0% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 23 | 23 | $13,225 | $1,297 | 9.8% |
| 11102 | Tangential biopsy of single skin lesion | Office | 2021 | 28 | 30 | $17,803 | $666.02 | 3.7% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Office | 2021 | 16 | 18 | $4,338 | $551.48 | 12.7% |
| 11104 | Punch biopsy of single skin lesion | Office | 2021 | 16 | 17 | $12,831 | $434.76 | 3.4% |
| 17003 | Destruction of 2-14 skin growths | Office | 2021 | 45 | 240 | $12,480 | $404.38 | 3.2% |
About Dr. Ruby Ghadially, M.D
Dr. Ruby Ghadially, M.D is a Specialist healthcare provider based in San Francisco, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/30/2006. The National Provider Identifier (NPI) number assigned to this provider is 1881703882.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ruby Ghadially, M.D has received a total of $467.21 in payments from pharmaceutical and medical device companies, with $69.44 received in 2023. These payments were reported across 8 transactions from 5 companies. The most common payment nature is "Food and Beverage" ($451.94).
As a Medicare-enrolled provider, Ghadially has provided services to 1,223 Medicare beneficiaries, totaling 2,166 services with total Medicare billing of $71,213. Data is available for 4 years (2020–2023), covering 34 distinct procedure/service records.
Practice Information
- Specialty Specialist
- Location San Francisco, CA
- Active Since 08/30/2006
- Last Updated 07/08/2007
- Taxonomy Code 174400000X
- Entity Type Individual
- NPI Number 1881703882
Products in Payments
- COSENTYX (Biological) $130.27
- Morphine Sulfate (Drug) $80.62
- SKYRIZI (Biological) $45.54
- CIBINQO (Drug) $15.27
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Specialist Doctors in San Francisco
Dr. Ari Baron, M.d, M.D
Specialist — Payments: $930,952
Dr. Jeffrey Wolf, M.d, M.D
Specialist — Payments: $458,581
Dr. Marc Simon, Md, MD
Specialist — Payments: $151,206
Dr. Bruce Mccormack, Md, MD
Specialist — Payments: $140,445
Dr. Christopher Pilcher, M.d, M.D
Specialist — Payments: $110,726
Dr. Bertrand Tuan, M.d, M.D
Specialist — Payments: $96,251